<table id="id_64833565-0087-4a0c-b023-05cd64832474" width="1014.000" xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<caption id="id_7f126422-6256-4d51-a0e9-7adc0252565e">Table 5 Drug Interactions: Changes in Pharmacokinetic Parameters for Coadministered Drug in the Presence of Nevirapine (All Interaction Trials Were Conducted in HIV-1 Positive Subjects)</caption>
<col width="15.1%"></col>
<col width="14.3%"></col>
<col width="14.3%"></col>
<col width="14.3%"></col>
<col width="13.4%"></col>
<col width="14.3%"></col>
<col width="14.3%"></col>
<tbody>
<tr id="id_db18fda6-cb2f-4e7a-90a6-0a5507c1e78e">
<td align="left" stylecode="Botrule Toprule Rrule Lrule" valign="top">
<content stylecode="bold">Coadministered Drug</content>
</td>
<td align="center" stylecode="Botrule Rrule" valign="top">
<content stylecode="bold">Dose of Coadministered Drug</content>
</td>
<td align="center" stylecode="Botrule Rrule" valign="top">
<content stylecode="bold">Dose Regimen of Nevirapine</content>
</td>
<td align="center" stylecode="Botrule Rrule" valign="top">
<content stylecode="bold">n</content>
</td>
<td align="center" colspan="3" stylecode="Botrule Rrule" valign="top">
<content stylecode="bold">% Change of Coadministered Drug Pharmacokinetic Parameters (90% CI)</content>
</td>
</tr>
<tr id="id_b45722d0-dbdf-4634-8f4f-175e33b9fd94">
<td align="left" stylecode="Lrule Botrule Rrule" valign="top">
<content stylecode="bold">Antiretrovirals</content>
</td>
<td align="center" stylecode="Botrule Rrule" valign="top"></td>
<td align="center" stylecode="Botrule Rrule" valign="top"></td>
<td align="center" stylecode="Botrule Rrule" valign="top"></td>
<td align="center" stylecode="Botrule Rrule" valign="top">
<content stylecode="bold">AUC</content>
</td>
<td align="center" stylecode="Botrule Rrule" valign="top">
<content stylecode="bold">C<sub>max</sub>
</content>
</td>
<td align="center" stylecode="Botrule Rrule" valign="top">
<content stylecode="bold">C<sub>min</sub>
</content>
</td>
</tr>
<tr id="id_c26e6b50-1195-4628-9ac3-2ccb273b8f33">
<td align="left" rowspan="2" stylecode="Lrule Botrule Rrule" valign="top">Atazanavir/Ritonavir<footnote id="id-d290b38a-9752-424f-8cc3-4249acce972b">For information regarding clinical recommendations, <content stylecode="italics">see <linkhtml href="#i4i_interactions_id_556b908b-c1bf-4d0c-b78d-558f3e2f2188">Drug Interactions (7)</linkhtml>
</content>.</footnote>
<footnote id="id-d6b85222-fec4-438e-8ee7-ec56a9a69147">Parallel group design; n = 23 for atazanavir/ritonavir + nevirapine, n = 22 for atazanavir/ritonavir without nevirapine. Changes in atazanavir PK are relative to atazanavir/ritonavir 300 mg/100 mg alone.</footnote>
</td>
<td align="center" rowspan="2" stylecode="Botrule Rrule" valign="top">300 mg/100 mg QD day 4 to 13, then 400 mg/100 mg QD, day 14 to 23</td>
<td align="center" rowspan="2" stylecode="Botrule Rrule" valign="top">200 mg BID day 1 to 23. Subjects were treated with nevirapine prior to trial entry.</td>
<td align="center" rowspan="2" stylecode="Botrule Rrule" valign="top">23</td>
<td align="center" stylecode="Botrule Rrule" valign="top">
<content stylecode="underline">Atazanavir <br/>300 mg/100 mg</content>
<br/>
<br/>↓42 <br/>(↓52 to ↓29)</td>
<td align="center" stylecode="Botrule Rrule" valign="top">
<content stylecode="underline">Atazanavir <br/>300 mg/100 mg</content>
<br/>
<br/>↓28 <br/>(↓40 to ↓14)</td>
<td align="center" stylecode="Botrule Rrule" valign="top">
<content stylecode="underline">Atazanavir <br/>300 mg/100 mg</content>
<br/>
<br/>↓72 <br/>(↓80 to ↓60)</td>
</tr>
<tr id="id_8f211068-274c-4e71-a639-f2225a73477d">
<td align="center" stylecode="Lrule Botrule Rrule" valign="top">
<content stylecode="underline">Atazanavir <br/>400 mg/100 mg</content>
<br/>
<br/>↓19 <br/>(↓35 to ↑2)</td>
<td align="center" stylecode="Botrule Rrule" valign="top">
<content stylecode="underline">Atazanavir <br/>400 mg/100 mg</content>
<br/>
<br/>↑2 <br/>(↓15 to ↑24)</td>
<td align="center" stylecode="Botrule Rrule" valign="top">
<content stylecode="underline">Atazanavir <br/>400 mg/100 mg</content>
<br/>
<br/>↓59 <br/>(↓73 to ↓40)</td>
</tr>
<tr id="id_6f12595b-024c-48ed-be32-6ccfdd822574">
<td align="left" stylecode="Lrule Botrule Rrule" valign="top">Darunavir/Ritonavir<footnote id="id-cd2b0766-0a6d-4fe3-ac44-7d476fd32c45">Based on between-trial comparison.</footnote>
</td>
<td align="center" stylecode="Botrule Rrule" valign="top">400 mg/100 mg BID</td>
<td align="center" stylecode="Botrule Rrule" valign="top">200 mg BID</td>
<td align="center" stylecode="Botrule Rrule" valign="top">8</td>
<td align="center" stylecode="Botrule Rrule" valign="top">↑24 <br/>(↓3 to ↑57)</td>
<td align="center" stylecode="Botrule Rrule" valign="top">↑40 <br/>(↑14 to ↑73)</td>
<td align="center" stylecode="Botrule Rrule" valign="top">↑2 <br/>(↓21 to ↑32)</td>
</tr>
<tr id="id_30de3056-57c2-497a-8dfb-dea2669686fc">
<td align="left" stylecode="Lrule Botrule Rrule" valign="top">Didanosine</td>
<td align="center" stylecode="Botrule Rrule" valign="top">100 mg to 150 mg BID</td>
<td align="center" stylecode="Botrule Rrule" valign="top">200 mg QD x 14 days; 200 mg BID x 14 days</td>
<td align="center" stylecode="Botrule Rrule" valign="top">18</td>
<td align="center" stylecode="Botrule Rrule" valign="top">↔</td>
<td align="center" stylecode="Botrule Rrule" valign="top">↔</td>
<td align="center" stylecode="Botrule Rrule" valign="top">
<footnote id="id-b7af9a6a-b03d-4c18-9105-58a4f6873de0">C<sub>min</sub> below detectable level of the assay</footnote>
</td>
</tr>
<tr id="id_8227a962-e896-498f-ae34-0f3b37168276">
<td align="left" stylecode="Lrule Botrule Rrule" valign="top">Efavirenz<footnoteref idref="id-d290b38a-9752-424f-8cc3-4249acce972b"></footnoteref>
</td>
<td align="center" stylecode="Botrule Rrule" valign="top">600 mg QD </td>
<td align="center" stylecode="Botrule Rrule" valign="top">200 mg QD x 14 days; 400 mg QD x 14 days </td>
<td align="center" stylecode="Botrule Rrule" valign="top">17 </td>
<td align="center" stylecode="Botrule Rrule" valign="top">↓28 <br/>(↓34 to ↓14) </td>
<td align="center" stylecode="Botrule Rrule" valign="top">↓12 <br/>(↓23 to ↑1) </td>
<td align="center" stylecode="Botrule Rrule" valign="top">↓32 <br/>(↓35 to ↓19) </td>
</tr>
<tr id="id_127ce12d-347e-48d8-85e1-1ca8558e47b0">
<td align="left" stylecode="Lrule Botrule Rrule" valign="top">Fosamprenavir </td>
<td align="center" stylecode="Botrule Rrule" valign="top">1400 mg BID </td>
<td align="center" stylecode="Botrule Rrule" valign="top">200 mg BID. Subjects were treated with nevirapine prior to trial entry. </td>
<td align="center" stylecode="Botrule Rrule" valign="top">17 </td>
<td align="center" stylecode="Botrule Rrule" valign="top">↓33 <br/>(↓45 to ↓20) </td>
<td align="center" stylecode="Botrule Rrule" valign="top">↓25 <br/>(↓37 to ↓10) </td>
<td align="center" stylecode="Botrule Rrule" valign="top">↓35 <br/>(↓50 to ↓15) </td>
</tr>
<tr id="id_02a478cf-18bc-45d2-a332-52d8480e5bb2">
<td align="left" stylecode="Lrule Botrule Rrule" valign="top">Fosamprenavir/Ritonavir </td>
<td align="center" stylecode="Botrule Rrule" valign="top">700 mg/100 mg BID </td>
<td align="center" stylecode="Botrule Rrule" valign="top">200 mg BID. Subjects were treated with nevirapine prior to trial entry </td>
<td align="center" stylecode="Botrule Rrule" valign="top">17 </td>
<td align="center" stylecode="Botrule Rrule" valign="top">↓11 <br/>(↓23 to ↑3) </td>
<td align="center" stylecode="Botrule Rrule" valign="top">↔</td>
<td align="center" stylecode="Botrule Rrule" valign="top">↓19 <br/>(↓32 to ↓4) </td>
</tr>
<tr id="id_2213bfff-f098-4b6a-84eb-0599aec0e232">
<td align="left" stylecode="Lrule Botrule Rrule" valign="top">Indinavir <footnoteref idref="id-d290b38a-9752-424f-8cc3-4249acce972b"></footnoteref>
</td>
<td align="center" stylecode="Botrule Rrule" valign="top">800 mg q8H </td>
<td align="center" stylecode="Botrule Rrule" valign="top">200 mg QD x 14 days; 200 mg BID x 14 days </td>
<td align="center" stylecode="Botrule Rrule" valign="top">19 </td>
<td align="center" stylecode="Botrule Rrule" valign="top">↓31 <br/>(↓39 to ↓22) </td>
<td align="center" stylecode="Botrule Rrule" valign="top">↓15 <br/>(↓24 to ↓4) </td>
<td align="center" stylecode="Botrule Rrule" valign="top">↓44 <br/>(↓53 to ↓33) </td>
</tr>
<tr id="id_53e2f689-4dd4-4952-9d97-df87642305dc">
<td align="left" stylecode="Lrule Botrule Rrule" valign="top">Lopinavir<footnoteref idref="id-d290b38a-9752-424f-8cc3-4249acce972b"></footnoteref>
<footnote id="id-5d9adf7e-432c-4c3b-bbd8-735d2e20d10e">Pediatric subjects ranging in age from 6 months to 12 years</footnote>
</td>
<td align="center" stylecode="Botrule Rrule" valign="top">300 mg/75 mg/m<sup>2</sup> (lopinavir/ ritonavir)<footnoteref idref="id-5d9adf7e-432c-4c3b-bbd8-735d2e20d10e"></footnoteref>
</td>
<td align="center" stylecode="Botrule Rrule" valign="top">7 mg/kg or 4 mg/kg QD x 2 weeks; BID x 1 week </td>
<td align="center" stylecode="Botrule Rrule" valign="top">12, 15<footnote id="id-8500f460-4306-40b7-8bc8-34fa97138813">Parallel group design; n for nevirapine + lopinavir/ritonavir, n for lopinavir/ritonavir alone.</footnote>
</td>
<td align="center" stylecode="Botrule Rrule" valign="top">↓22 <br/>(↓44 to ↑9) </td>
<td align="center" stylecode="Botrule Rrule" valign="top">↓14 <br/>(↓36 to ↑16) </td>
<td align="center" stylecode="Botrule Rrule" valign="top">↓55 <br/>(↓75 to ↓19) </td>
</tr>
<tr id="id_667e3d28-de17-4822-8fd0-580418032ed3">
<td align="left" stylecode="Lrule Botrule Rrule" valign="top">Lopinavir <footnoteref idref="id-d290b38a-9752-424f-8cc3-4249acce972b"></footnoteref>
</td>
<td align="center" stylecode="Botrule Rrule" valign="top">400 mg/100 mg BID (lopinavir/ ritonavir) </td>
<td align="center" stylecode="Botrule Rrule" valign="top">200 mg QD x 14 days; 200 mg BID <br/>&gt; 1 year </td>
<td align="center" stylecode="Botrule Rrule" valign="top">22, 19<footnoteref idref="id-8500f460-4306-40b7-8bc8-34fa97138813"></footnoteref>
</td>
<td align="center" stylecode="Botrule Rrule" valign="top">↓27 <br/>(↓47 to ↓2) </td>
<td align="center" stylecode="Botrule Rrule" valign="top">↓19 <br/>(↓38 to ↑5) </td>
<td align="center" stylecode="Botrule Rrule" valign="top">↓51 <br/>(↓72 to ↓26) </td>
</tr>
<tr id="id_31459ae7-6d72-4d0c-8d0d-0b1716106d2e">
<td align="left" stylecode="Lrule Botrule Rrule" valign="top">Maraviroc<footnote id="id-3d1b9121-1290-4d64-a052-b0f16a842042">Based on historical controls.</footnote>
</td>
<td align="center" stylecode="Botrule Rrule" valign="top">300 mg SD </td>
<td align="center" stylecode="Botrule Rrule" valign="top">200 mg BID </td>
<td align="center" stylecode="Botrule Rrule" valign="top">8 </td>
<td align="center" stylecode="Botrule Rrule" valign="top">↑1 <br/>(↓35 to ↑55) </td>
<td align="center" stylecode="Botrule Rrule" valign="top">↑54 <br/>(↓6 to ↑151) </td>
<td align="center" stylecode="Botrule Rrule" valign="top">↔</td>
</tr>
<tr id="id_4065f9bc-42a0-46fa-b276-56292625043a">
<td align="left" stylecode="Lrule Rrule" valign="top">Nelfinavir <footnoteref idref="id-d290b38a-9752-424f-8cc3-4249acce972b"></footnoteref>
</td>
<td align="center" rowspan="2" stylecode="Botrule Rrule" valign="top">750 mg TID </td>
<td align="center" rowspan="2" stylecode="Botrule Rrule" valign="top">200 mg QD x 14 days; 200 mg BID x 14 days </td>
<td align="center" rowspan="2" stylecode="Botrule Rrule" valign="top">23 </td>
<td align="center" stylecode="Botrule Rrule" valign="top">↔</td>
<td align="center" stylecode="Botrule Rrule" valign="top">↔</td>
<td align="center" stylecode="Botrule Rrule" valign="top">↓32 <br/>(↓50 to ↑5) </td>
</tr>
<tr id="id_6f15f5cd-9e52-4e0d-ad7d-2359627db3a4">
<td align="left" stylecode="Lrule Botrule Rrule" valign="top">Nelfinavir-M8 metabolite</td>
<td align="center" stylecode="Botrule Rrule" valign="top">↓62 <br/>(↓70 to ↓53) </td>
<td align="center" stylecode="Botrule Rrule" valign="top">↓59 <br/>(↓68 to ↓48) </td>
<td align="center" stylecode="Botrule Rrule" valign="top">↓66 <br/>(↓74 to ↓55) </td>
</tr>
<tr id="id_3ba0532e-45bc-4a4a-aef1-65bca2278c19">
<td align="left" stylecode="Lrule Botrule Rrule" valign="top">Ritonavir </td>
<td align="center" stylecode="Botrule Rrule" valign="top">600 mg BID </td>
<td align="center" stylecode="Botrule Rrule" valign="top">200 mg QD x 14 days; 200 mg BID x 14 days </td>
<td align="center" stylecode="Botrule Rrule" valign="top">18 </td>
<td align="center" stylecode="Botrule Rrule" valign="top">↔</td>
<td align="center" stylecode="Botrule Rrule" valign="top">↔</td>
<td align="center" stylecode="Botrule Rrule" valign="top">↔</td>
</tr>
<tr id="id_e2cbec61-d807-4649-91d1-4a6789a762c4">
<td align="left" stylecode="Lrule Botrule Rrule" valign="top">Stavudine </td>
<td align="center" stylecode="Botrule Rrule" valign="top">30 mg to 40 mg BID </td>
<td align="center" stylecode="Botrule Rrule" valign="top">200 mg QD x 14 days; 200 mg BID x 14 days </td>
<td align="center" stylecode="Botrule Rrule" valign="top">22 </td>
<td align="center" stylecode="Botrule Rrule" valign="top">↔</td>
<td align="center" stylecode="Botrule Rrule" valign="top">↔</td>
<td align="center" stylecode="Botrule Rrule" valign="top">
<footnoteref idref="id-b7af9a6a-b03d-4c18-9105-58a4f6873de0"></footnoteref>
</td>
</tr>
<tr id="id_2c2331d9-7951-4aa1-9a1d-e093d679b7d9">
<td align="left" stylecode="Lrule Botrule Rrule" valign="top">Zalcitabine </td>
<td align="center" stylecode="Botrule Rrule" valign="top">0.125 mg to <br/>0.25 mg TID </td>
<td align="center" stylecode="Botrule Rrule" valign="top">200 mg QD x 14 days; 200 mg BID x 14 days </td>
<td align="center" stylecode="Botrule Rrule" valign="top">6 </td>
<td align="center" stylecode="Botrule Rrule" valign="top">↔</td>
<td align="center" stylecode="Botrule Rrule" valign="top">↔</td>
<td align="center" stylecode="Botrule Rrule" valign="top">
<footnoteref idref="id-b7af9a6a-b03d-4c18-9105-58a4f6873de0"></footnoteref>
</td>
</tr>
<tr id="id_c101ed7a-ddef-42af-af7e-f81c05b104ca">
<td align="left" stylecode="Lrule Botrule Rrule" valign="top">Zidovudine </td>
<td align="center" stylecode="Botrule Rrule" valign="top">100 mg to 200 mg TID </td>
<td align="center" stylecode="Botrule Rrule" valign="top">200 mg QD x 14 days; 200 mg BID x 14 days </td>
<td align="center" stylecode="Botrule Rrule" valign="top">11 </td>
<td align="center" stylecode="Botrule Rrule" valign="top">↓28 <br/>(↓40 to ↓4) </td>
<td align="center" stylecode="Botrule Rrule" valign="top">↓30 <br/>(↓51 to ↑14) </td>
<td align="center" stylecode="Botrule Rrule" valign="top">
<footnoteref idref="id-b7af9a6a-b03d-4c18-9105-58a4f6873de0"></footnoteref>
</td>
</tr>
<tr id="id_88227933-6f2b-40f3-ae27-1810637f7b1b">
<td align="left" stylecode="Lrule Botrule Rrule" valign="top">
<content stylecode="bold">Other Medications </content>
</td>
<td align="center" stylecode="Botrule Rrule" valign="top"></td>
<td align="center" stylecode="Botrule Rrule" valign="top"></td>
<td align="center" stylecode="Botrule Rrule" valign="top"></td>
<td align="center" stylecode="Botrule Rrule" valign="top">
<content stylecode="bold">AUC </content>
</td>
<td align="center" stylecode="Botrule Rrule" valign="top">
<content stylecode="bold">C<sub>max</sub>
</content>
</td>
<td align="center" stylecode="Botrule Rrule" valign="top">
<content stylecode="bold">C<sub>min</sub>
</content>
</td>
</tr>
<tr id="id_f88cf612-30f6-4edd-ab2c-9be733e34452">
<td align="left" stylecode="Lrule Rrule" valign="top">Clarithromycin <footnoteref idref="id-d290b38a-9752-424f-8cc3-4249acce972b"></footnoteref>
</td>
<td align="center" rowspan="2" stylecode="Botrule Rrule" valign="top">500 mg BID </td>
<td align="center" rowspan="2" stylecode="Botrule Rrule" valign="top">200 mg QD x 14 days; 200 mg BID x 14 days </td>
<td align="center" rowspan="2" stylecode="Botrule Rrule" valign="top">15 </td>
<td align="center" stylecode="Botrule Rrule" valign="top">↓31 <br/>(↓38 to ↓24) </td>
<td align="center" stylecode="Botrule Rrule" valign="top">↓23 <br/>(↓31 to ↓14) </td>
<td align="center" stylecode="Botrule Rrule" valign="top">↓56 <br/>(↓70 to ↓36) </td>
</tr>
<tr id="id_368211bc-2bff-4fb6-a9d9-26769019e003">
<td align="left" stylecode="Lrule Botrule Rrule" valign="top">Metabolite <br/>14-OH-clarithromycin </td>
<td align="center" stylecode="Botrule Rrule" valign="top">↑42 <br/>(↑16 to ↑73) </td>
<td align="center" stylecode="Botrule Rrule" valign="top">↑47 <br/>(↑21 to ↑80) </td>
<td align="center" stylecode="Botrule Rrule" valign="top">↔</td>
</tr>
<tr id="id_adfbd92b-db00-484f-94f2-82a2bc9ae757">
<td align="left" rowspan="2" stylecode="Lrule Botrule Rrule" valign="top">Ethinyl estradiol <footnoteref idref="id-d290b38a-9752-424f-8cc3-4249acce972b"></footnoteref>
<br/>
<br/>and <br/>
<br/>Norethindrone <footnoteref idref="id-d290b38a-9752-424f-8cc3-4249acce972b"></footnoteref>
</td>
<td align="center" rowspan="2" stylecode="Botrule Rrule" valign="top">0.035 mg (as Ortho-Novum<sup>®**</sup> 1/35) <br/>
<br/>
<br/>1 mg (as Ortho-Novum<sup>®**</sup> 1/35) </td>
<td align="center" rowspan="2" stylecode="Botrule Rrule" valign="top">200 mg QD x 14 days; 200 mg BID x 14 days </td>
<td align="center" rowspan="2" stylecode="Botrule Rrule" valign="top">10 </td>
<td align="center" stylecode="Botrule Rrule" valign="top">↓20 <br/>(↓33 to ↓3)<br/>
<br/>
</td>
<td align="center" stylecode="Botrule Rrule" valign="top">↔</td>
<td align="center" stylecode="Botrule Rrule" valign="top">
<footnoteref idref="id-b7af9a6a-b03d-4c18-9105-58a4f6873de0"></footnoteref>
</td>
</tr>
<tr id="id_5e054d4a-327e-4f6e-aaa3-53786ebe5297">
<td align="center" stylecode="Lrule Botrule Rrule" valign="top">↓19 <br/>(↓30 to ↓7) </td>
<td align="center" stylecode="Botrule Rrule" valign="top">↓16 <br/>(↓27 to ↓3) </td>
<td align="center" stylecode="Botrule Rrule" valign="top">
<footnoteref idref="id-b7af9a6a-b03d-4c18-9105-58a4f6873de0"></footnoteref>
</td>
</tr>
<tr id="id_d770cdc0-b461-4b25-95de-9679625c286a">
<td align="left" stylecode="Lrule Botrule Rrule" valign="top">Depomedroxy-<br/>progesterone acetate </td>
<td align="center" stylecode="Botrule Rrule" valign="top">150 mg every 3 months </td>
<td align="center" stylecode="Botrule Rrule" valign="top">200 mg QD x 14 days; 200 mg BID x 14 days </td>
<td align="center" stylecode="Botrule Rrule" valign="top">32 </td>
<td align="center" stylecode="Botrule Rrule" valign="top">↔</td>
<td align="center" stylecode="Botrule Rrule" valign="top">↔</td>
<td align="center" stylecode="Botrule Rrule" valign="top">↔</td>
</tr>
<tr id="id_00de98fe-5e61-4170-9840-79404efa6883">
<td align="left" stylecode="Lrule Botrule Rrule" valign="top">Fluconazole </td>
<td align="center" stylecode="Botrule Rrule" valign="top">200 mg QD </td>
<td align="center" stylecode="Botrule Rrule" valign="top">200 mg QD x 14 days; 200 mg BID x 14 days </td>
<td align="center" stylecode="Botrule Rrule" valign="top">19 </td>
<td align="center" stylecode="Botrule Rrule" valign="top">↔</td>
<td align="center" stylecode="Botrule Rrule" valign="top">↔</td>
<td align="center" stylecode="Botrule Rrule" valign="top">↔</td>
</tr>
<tr id="id_8af35f42-8ac6-4185-bd59-524553b5f80d">
<td align="left" stylecode="Lrule Botrule Rrule" valign="top">Ketoconazole <footnoteref idref="id-d290b38a-9752-424f-8cc3-4249acce972b"></footnoteref>
</td>
<td align="center" stylecode="Botrule Rrule" valign="top">400 mg QD </td>
<td align="center" stylecode="Botrule Rrule" valign="top">200 mg QD x 14 days; 200 mg BID x 14 days </td>
<td align="center" stylecode="Botrule Rrule" valign="top">21 </td>
<td align="center" stylecode="Botrule Rrule" valign="top">↓72 <br/>(↓80 to ↓60) </td>
<td align="center" stylecode="Botrule Rrule" valign="top">↓44 <br/>(↓58 to ↓27) </td>
<td align="center" stylecode="Botrule Rrule" valign="top">
<footnoteref idref="id-b7af9a6a-b03d-4c18-9105-58a4f6873de0"></footnoteref>
</td>
</tr>
<tr id="id_503d9428-ffb5-4959-8e9c-194b5838480e">
<td align="left" stylecode="Lrule Botrule Rrule" valign="top">Methadone <footnoteref idref="id-d290b38a-9752-424f-8cc3-4249acce972b"></footnoteref>
</td>
<td align="center" stylecode="Botrule Rrule" valign="top">Individual Subject Dosing </td>
<td align="center" stylecode="Botrule Rrule" valign="top">200 mg QD x 14 days; 200 mg BID ≥ 7 days </td>
<td align="center" stylecode="Botrule Rrule" valign="top">9 </td>
<td align="center" colspan="3" stylecode="Botrule Rrule" valign="top">In a controlled pharmacokinetic trial with nine subjects receiving chronic methadone to whom steady-state nevirapine therapy was added, the clearance of methadone was increased by 3-fold, resulting in symptoms of withdrawal, requiring dose adjustments in 10 mg segments, in seven of the nine subjects. Methadone did not have any effect on nevirapine clearance. </td>
</tr>
<tr id="id_80f4d4dd-1a61-41f9-b765-cccf5ce3cac0">
<td align="left" stylecode="Lrule Botrule Rrule" valign="top">Rifabutin <footnoteref idref="id-d290b38a-9752-424f-8cc3-4249acce972b"></footnoteref>
</td>
<td align="center" rowspan="2" stylecode="Botrule Rrule" valign="top">150 mg or 300 mg QD </td>
<td align="center" rowspan="2" stylecode="Botrule Rrule" valign="top">200 mg QD x 14 days; 200 mg BID x 14 days </td>
<td align="center" rowspan="2" stylecode="Botrule Rrule" valign="top">19 </td>
<td align="center" stylecode="Botrule Rrule" valign="top">↑17 <br/>(↓2 to ↑40) </td>
<td align="center" stylecode="Botrule Rrule" valign="top">↑28 <br/>(↑9 to ↑51) </td>
<td align="center" stylecode="Botrule Rrule" valign="top">↔</td>
</tr>
<tr id="id_d22a951a-a31c-43e7-b87e-c2eb1fe106b8">
<td align="left" stylecode="Lrule Botrule Rrule" valign="top">Metabolite 25-O-desacetyl-rifabutin </td>
<td align="center" stylecode="Botrule Rrule" valign="top">↑24 <br/>(↓16 to ↑84) </td>
<td align="center" stylecode="Botrule Rrule" valign="top">↑29 <br/>(↓2 to ↑68) </td>
<td align="center" stylecode="Botrule Rrule" valign="top">↑22 <br/>(↓14 to ↑74) </td>
</tr>
<tr id="id_655c1fae-7ac4-4a80-bd4f-153e90605a46">
<td align="left" stylecode="Lrule Botrule Rrule" valign="top">Rifampin <footnoteref idref="id-d290b38a-9752-424f-8cc3-4249acce972b"></footnoteref>
</td>
<td align="center" stylecode="Botrule Rrule" valign="top">600 mg QD </td>
<td align="center" stylecode="Botrule Rrule" valign="top">200 mg QD x 14 days; 200 mg BID x 14 days </td>
<td align="center" stylecode="Botrule Rrule" valign="top">14 </td>
<td align="center" stylecode="Botrule Rrule" valign="top">↑11 <br/>(↓4 to ↑28) </td>
<td align="center" stylecode="Botrule Rrule" valign="top">↔</td>
<td align="center" stylecode="Botrule Rrule" valign="top">
<footnoteref idref="id-b7af9a6a-b03d-4c18-9105-58a4f6873de0"></footnoteref>
</td>
</tr>
<tr id="id_f8880cee-7787-4fae-a701-f8bf03b7bf1a">
<td align="left" colspan="7" stylecode="Lrule Botrule Rrule" valign="top">↑ = Increase, ↓ = Decrease, ↔ = No Effect</td>
</tr>
</tbody>
</table>